Dimerix Secures U.S. IND for New Asset DMX-652
Key points
- Dimerix acquired DMX-652, a Phase 2-ready renal asset
- Successful transfer of U.S. IND sponsorship to Dimerix
- DMX-652 set for Phase 2 trial in acute kidney injury
Full summary
Dimerix Limited (ASX: DXB) has announced the acquisition of DMX-652, a Phase 2-ready renal asset, and successfully completed the transfer of its U.S. Investigational New Drug (IND) sponsorship from Mission Therapeutics. DMX-652, a selective inhibitor of USP30, is designed to support mitochondrial quality control in injured kidney cells. The asset is set to enter a Phase 2 clinical trial for acute kidney injury (AKI) associated with cardiac surgery. The transfer of the IND represents a significant milestone, providing Dimerix with direct control over clinical development activities in the U.S. DMX-652 has shown promising pre-clinical data and encouraging safety and pharmacokinetic data from Phase 1 trials.
Summary generated by a large language model. Please interpret with care.